Welcome and Methods

- Introduction
- Methods
- Table 1. Summary of the Process and Methods for the Guidance Development
- Table 2. Rating System Used to Rate Level of Evidence and Strength of Recommendation
- Table 3. Commonly Used Abbreviations

Test, Evaluate, Monitor

- Testing, Evaluation, and Monitoring of Hepatitis C
- HCV Testing and Linkage to Care
- When and in Whom to Initiate HCV Therapy
- Overview of Cost, Reimbursement, and Cost-Effectiveness Considerations for Hepatitis C Treatment Regimens
- Monitoring Patients Who Are Starting HCV Treatment, Are on Treatment, or Have Completed Therapy
- HCV Resistance Primer

Treatment-Naive

- Initial Treatment of Adults with HCV Infection
- Simplified HCV Treatment* for Treatment-Naive Adults Without Cirrhosis
- Simplified HCV Treatment Algorithm for Treatment-Naive Adults With Compensated Cirrhosis
- Treatment-Naive Genotype 1
- Treatment-Naive Genotype 1a Without Cirrhosis
- Treatment-Naive Genotype 1a With Compensated Cirrhosis
- Treatment-Naive Genotype 1b Without Cirrhosis
- Treatment-Naive Genotype 1b With Compensated Cirrhosis
- Treatment-Naive Genotype 2
- Treatment-Naive Genotype 2 Without Cirrhosis
- Treatment-Naive Genotype 2 With Compensated Cirrhosis
- Treatment-Naive Genotype 3
- Treatment-Naive Genotype 3 Without Cirrhosis
- Treatment-Naive Genotype 3 With Compensated Cirrhosis
- Treatment-Naive Genotype 4
- Treatment-Naive Genotype 4 Without Cirrhosis
- Treatment-Naive Genotype 4 With Compensated Cirrhosis
- Treatment-Naive Genotype 5 or 6

Treatment-Experienced

- Retreatment of Persons in Whom Prior Therapy Failed
- Treatment-Experienced Genotype 1
- Peginterferon/Ribavirin-Experienced, Genotype 1a Patients Without Cirrhosis
- Peginterferon/Ribavirin-Experienced, Genotype 1a Patients With Compensated Cirrhosis
- Peginterferon/Ribavirin-Experienced, Genotype 1b Patients Without Cirrhosis
- Peginterferon/Ribavirin-Experienced, Genotype 1b Patients With Compensated Cirrhosis
### Table of Contents

<table>
<thead>
<tr>
<th>Section</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>NS3 Protease Inhibitor + Peginterferon/Ribavirin-Experienced, Genotype 1 Patients Without Cirrhosis</td>
<td></td>
</tr>
<tr>
<td>NS3 Protease Inhibitor + Peginterferon/Ribavirin-Experienced, Genotype 1 Patients With Compensated Cirrhosis</td>
<td></td>
</tr>
<tr>
<td>Non-NS5A Inhibitor, Sofosbuvir-Containing Regimen-Experienced, Genotype 1 Patients Without Cirrhosis</td>
<td></td>
</tr>
<tr>
<td>Non-NS5A Inhibitor, Sofosbuvir-Containing Regimen-Experienced, Genotype 1 Patients With Compensated Cirrhosis</td>
<td></td>
</tr>
<tr>
<td>NS5A Inhibitor DAA-Experienced (Excluding Glecaprevir/Pibrentasvir Failures), Genotype 1 Patients, With or Without Compensated Cirrhosis</td>
<td></td>
</tr>
<tr>
<td>Treatment-Experienced Genotype 2</td>
<td></td>
</tr>
<tr>
<td>Peginterferon/Ribavirin-Experienced, Genotype 2 Patients Without Cirrhosis</td>
<td></td>
</tr>
<tr>
<td>Peginterferon/Ribavirin-Experienced, Genotype 2 Patients With Compensated Cirrhosis</td>
<td></td>
</tr>
<tr>
<td>DAA-Experienced (Including NS5A Inhibitors Except Glecaprevir/Pibrentasvir Failures), Genotype 2 Patients, With or Without Compensated Cirrhosis</td>
<td></td>
</tr>
<tr>
<td>Treatment-Experienced Genotype 3</td>
<td></td>
</tr>
<tr>
<td>Peginterferon/Ribavirin-Experienced, Genotype 3 Patients Without Cirrhosis</td>
<td></td>
</tr>
<tr>
<td>Peginterferon/Ribavirin-Experienced, Genotype 3 Patients With Compensated Cirrhosis</td>
<td></td>
</tr>
<tr>
<td>DAA-Experienced (Including NS5A Inhibitors Except Glecaprevir/Pibrentasvir Failures), Genotype 3 Patients, With or Without Compensated Cirrhosis</td>
<td></td>
</tr>
<tr>
<td>Treatment-Experienced Genotype 4</td>
<td></td>
</tr>
<tr>
<td>Peginterferon/Ribavirin-Experienced, Genotype 4 Patients Without Cirrhosis</td>
<td></td>
</tr>
<tr>
<td>Peginterferon/Ribavirin-Experienced, Genotype 4 Patients With Compensated Cirrhosis</td>
<td></td>
</tr>
<tr>
<td>DAA-Experienced (Including NS5A Inhibitors Except Glecaprevir/Pibrentasvir Failures), Genotype 4 Patients, With or Without Compensated Cirrhosis</td>
<td></td>
</tr>
<tr>
<td>Treatment-Experienced Genotype 5 or 6</td>
<td></td>
</tr>
<tr>
<td>Peginterferon/Ribavirin-Experienced, Genotype 5 or 6 Patients With or Without Compensated Cirrhosis</td>
<td></td>
</tr>
<tr>
<td>DAA-Experienced (Including NS5A Inhibitors Except Glecaprevir/Pibrentasvir Failures), Genotype 5 or 6 Patients, With or Without Compensated Cirrhosis</td>
<td></td>
</tr>
<tr>
<td>Glecaprevir/Pibrentasvir Treatment Failure (All Genotypes)</td>
<td></td>
</tr>
<tr>
<td>Sofosbuvir/Velpatasvir/Voxilaprevir Treatment Failure (All Genotypes)</td>
<td></td>
</tr>
</tbody>
</table>

### Unique Populations

- Management of Unique & Key Populations With HCV Infection
- Patients With HIV/HCV Coinfection
- Patients With Decompensated Cirrhosis
- Patients Who Develop Recurrent HCV Infection Post Liver Transplantation
- Treatment of HCV-Uninfected Transplant Recipients Receiving Organs From HCV-Viremic Donors
- Patients with Renal Impairment
- Kidney Transplant Patients
- Management of Acute HCV Infection
- HCV in Pregnancy
- HCV in Children
- Management of Key Populations With Chronic HCV Infection
- Key Populations: Identification and Management of HCV in People Who Inject Drugs
- HCV in Key Populations: Men Who Have Sex With Men
- HCV Testing and Treatment in Correctional Settings

### References

- Reference list sorted by first author